vabysmo- faricimab injection, solution
genentech, inc. - faricimab (unii: qc4f7fkk7i) (faricimab - unii:qc4f7fkk7i) - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with: vabysmo is contraindicated in patients with ocular or periocular infections. vabysmo is contraindicated in patients with active intraocular inflammation. vabysmo is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients in vabysmo. hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation. risk summary there are no adequate and well-controlled studies of vabysmo administration in pregnant women. administration of vabysmo to pregnant monkeys throughout the period of organogenesis resulted in an increased incidence of abortions at intravenous (iv) doses 158 times the human exposure (based on cmax ) of the maximum recommended human dose [see animal data] . based on the mechanism of action of vegf and ang-2 inhibitors, there is a potential risk to female reproductive capacity, and t
vabysmo faricimab 120 mg/ml solution for injection vial
roche products pty ltd - faricimab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; acetic acid; methionine; sodium chloride; sucrose; polysorbate 20; water for injections - vabysmo is indicated for the treatment of:,- neovascular (wet) age-related macular degeneration (namd),- diabetic macular oedema (dmo).
vabysmo
roche pharmaceuticals (israel) ltd - faricimab - solution for injection - faricimab 120 mg/ml - faricimab - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with:• neovascular (wet) age-related macular degeneration (namd) • diabetic macular edema (dme)
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
vabysmo solution
hoffmann-la roche limited - faricimab - solution - 6mg - faricimab 6mg
vabysmo
roche products (nz) ltd - faricimab 120 mg/ml - solution for injection - 120 mg/ml - active: faricimab 120 mg/ml excipient: acetic acid histidine methionine polysorbate 20 sodium chloride sucrose water for injection - vabysmo is indicated for the treatment of: · neovascular (wet) age-related macular degeneration (namd)
vabysmo solution for injection 6mg0.05ml
roche singapore pte. ltd. - faricimab - injection, solution - faricimab 6.00mg/0.05ml
vabysmo 28.8mg/0.24ml solution for injection vials
roche products ltd - faricimab - solution for injection - 120mg/1ml
vabysmo 6 mg/0.05 ml (120 mg/ml) solution for intravitreal injection
f. hoffman-la roche ltd.; importer: roche (philippines), inc.; distributor: roche (philippines), inc. - faricimab - solution for intravitreal injection - 6 mg/0.05 ml (120 mg/ml)
vabysmo 6 mg per 0.05 ml solution for injection
f.hoffmann-la roche ltd., switzerland - faricimab - solution for injection - 120 mg/ml,